CEACAM5 and neoplasm: In our pilot study we reported for the first time that PIVKA-II is significantly higher in PDAC than in benign pancreatic diseases and that it shows a rather good diagnostic performance compared to commonly used tumor markers Carbohydrate Antigen 19.9 (CA 19.9), Carcino-Embryonic Antigen (CEA) and CA242 [7].